Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study.

Date publication

mai 2019

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre , Dr VUITTON Lucine , Pr PEYRIN-BIROULET Laurent , Pr REIMUND Jean-Marie

Tous les auteurs :
Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31056693

Résumé

Whether vedolizumab may be effective as a treatment for primary sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD) remains controversial.

Mots clés

Crohn’s disease, inflammatory bowel disease, primary sclerosing cholangitis, ulcerative colitis, vedolizumab

Référence

J Crohns Colitis. 2019 May 6;: